Why Formulation Development Now Starts With Manufacturing
Formulation development is moving beyond drug delivery to shape manufacturing, quality, scale-up, and supply resilience across modern pharmaceutical operations.
Formulation development is becoming a manufacturing strategy, not simply a drug delivery exercise.
As pharmaceutical pipelines move towards biologics, nanoparticles, long-acting products, and increasingly complex molecules, formulation choices increasingly determine whether a product can be scaled, controlled, transferred, and supplied reliably.
This convergence is seen across formulation science and pharmaceutical manufacturing, highlighting the importance of continuous processing, Process Analytical Technology (PAT), Quality-by-Design (QbD), automation, and digital experimentation as increasingly connected capabilities.
The Formulation Decision Is a Manufacturing Decision
The traditional development model often treats formulation as a scientific stage that precedes manufacturing. That is changing.
Poorly soluble small molecules, peptides, proteins, vaccines, nucleic acids, and advanced delivery systems can behave very differently when moved from laboratory conditions into commercial production.
The formulation must therefore be designed around both product performance and process performance.
There are several technologies shaping modern formulation development.
Nanoparticle systems can improve solubility, permeability, targeting, or controlled release, but they introduce new manufacturing variables such as particle size, surface characteristics, aggregation, and encapsulation efficiency.
The same principle applies to biologics. Protein and nucleic-acid formulations require careful control of pH, ionic strength, interfacial stress, and stability. High-concentration monoclonal antibody products add another problem: Increasing concentration can raise viscosity and complicate delivery through prefilled syringes or autoinjectors.
For Technical Operations teams, this changes the question. It is no longer enough to ask whether a formulation works.
The more important question is whether it can be manufactured consistently at the intended scale.
That makes formulation development an early indicator of future CMC risk, technology-transfer complexity, and commercial manufacturing readiness.
Advanced Formulations Are Raising the Manufacturing Bar
The most sophisticated drug delivery systems can create significant value, but they also demand greater process understanding.
Lipid nanoparticles, liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and nanosuspensions each present different scale-up requirements.
This creates certain risks ranging from aggregation and fusion to residual solvents, crystal growth, polymorphic transitions, and process sensitivity.
Scale-up is therefore not simply a larger version of laboratory production.
Changes in mixing, heat transfer, residence time, shear, drying, and material behaviour can alter the final product. This becomes particularly important for multiphase formulations where apparently small process changes can affect critical quality attributes.
Amorphous solid dispersions are also an important strategy for improving the developability of poorly soluble compounds. Hot-melt extrusion and spray-drying can improve drug dispersion, while inline near-infrared and Raman spectroscopy can provide additional process information.
The important thing is that formulation scientists and manufacturing engineers need to solve scale-up problems together, and earlier.
That principle also applies to sterile products and lyophilised biologics. Freeze-drying requires careful control of freezing, annealing, primary drying, and secondary drying. Changes to cycle conditions can affect cake structure, stability, and ultimately product performance.
The result is a broader definition of formulation success: A product must be stable, effective, manufacturable, transferable, and controllable.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Continuous Manufacturing Moves Control Closer to the Drug Product
Continuous manufacturing is one of the clearest examples of formulation and manufacturing converging.
Rather than processing discrete batches, continuous systems can integrate feeding, blending, granulation, tableting, and coating into a connected production process.
Potential benefits include smaller manufacturing footprints, reduced variability, faster release, and lower waste.
The U.S. Food and Drug Administration (FDA) guidance also recognises continuous manufacturing as an important route for modernising pharmaceutical production and strengthening process control.
The operational advantage comes from moving quality monitoring closer to the point of manufacture.
Process Analytical Technology (PAT) can provide real-time information about critical quality attributes; near-infrared spectroscopy can monitor blend uniformity; Raman spectroscopy can support polymorph monitoring, and other sensors can track particle characteristics and process behaviour.
The FDA’s PAT framework was specifically designed to support innovative approaches to pharmaceutical development, manufacturing, and quality assurance.
A 2024 dataset from an MSD continuous manufacturing line that captured 300 million data points across 120 hours, covering 75 process parameters, showed that predictive modelling from this dataset reduced downtime by 20%.
This illustrates the potential value of data-rich manufacturing, but they also expose the challenge. More data only creates value when companies have the analytical infrastructure, process models, and operational expertise to interpret it.
Pharmatica’s analysis of Quality-by-Design (QbD) explores the same shift towards embedding quality into development rather than relying on end-product testing.
QbD and Digital Development Are Connecting the Chain
Quality-by-Design provides the framework for bringing these capabilities together.
Rather than optimising individual formulation variables in isolation, QbD connects product knowledge, critical quality attributes, risk assessment, experimentation, process parameters, and control strategies.
The International Council for Harmonisation’s quality framework continues to support this science- and risk-based approach across pharmaceutical development and manufacturing.
Digital Design-of-Experiments (DoE) can extend this model. Bayesian optimisation, Gaussian processes, mechanistic models, and model-based control are all emerging tools for reducing experimental burden while exploring complex formulation and manufacturing relationships.
The opportunity is not to replace formulation scientists with AI but to give development teams better ways to learn from experiments.
DoE and QbD have already shifted development away from pure trial-and-error towards structured exploration of formulation variables, manufacturing parameters, and critical quality attributes.
The next step is greater integration between those experiments and manufacturing data.
That could enable the identification of formulation risks earlier, prediction of stability behaviour and model process variability, and establishing more robust operating ranges before commercial scale.
This emerging architecture is a chain linking knowledge graphs, digital DoE, mechanistic and machine-learning models, PAT, model predictive control, real-time release testing, and deviation prediction.
The value does not sit within one technology. It sits in the connection between formulation science, process engineering, analytical development, manufacturing, Quality, and regulatory strategy.
Formulation Development in Manufacturing Strategy
Formulation development can no longer be managed as an isolated R&D activity.
There are interconnected risks across physical instability, scale-up variability, regulatory delays, supply, and sustainability. Additionally, natural-excipient variability, solvent intensity, single-source materials, and technology-transfer complexity remain persistent industry challenges.
One reported example is particularly relevant to manufacturing strategy. Supply disruption and excipient shortages are associated with 10% to 20% cost increases.
The answer is not simply to add more testing.
Manufacturers need to build greater knowledge into development decisions from the beginning.
That means evaluating formulation options against:
- Scale-up and technology-transfer risk
- Material and excipient variability
- Process monitoring and control requirements
- Stability and packaging performance
- Regulatory expectations
- Manufacturing footprint, energy, waste, and supply resilience
Further tools to improve formulation development and manufacturing include AI-supported formulation screening, predictive stability modelling, digital twins, model-informed development, and greener manufacturing approaches.
The excipient market could reach $14 billion by 2033, with an R&D cost of $2.23 billion per asset as a reminder of the economic pressure surrounding pharmaceutical development.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Better Formulation Development for Better Manufacturing
The earlier manufacturing realities enter formulation decisions, the fewer downstream surprises reach the factory.
That is growing in importance as pharma moves towards more complex products and more data-rich production environments.
Pharmatica's coverage of digital CMC submissions similarly examines how manufacturing knowledge, regulatory processes, and digital infrastructure are becoming more closely connected across the product lifecycle.
Formulation development is therefore becoming one of the earliest points at which commercial manufacturing strategy is determined.
The developers best positioned to benefit will be those that connect formulation science to process understanding, digital experimentation, quality systems, and supply strategy before development decisions become difficult to change.
The Chain Reaction begins long before the production line starts.
At Pharmatica, we analyse the technologies, manufacturing strategies, and regulatory developments shaping pharmaceutical Technical Operations. Our focus is where scientific decisions become operational realities, and where better manufacturing intelligence can translate into more reliable medicines and resilient supply.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is pharmaceutical formulation development?
Pharmaceutical formulation development is the process of converting an active pharmaceutical ingredient into a stable, safe, effective, and manufacturable drug product. It considers factors such as dosage form, excipients, stability, delivery, manufacturability, and critical quality attributes.
Why is formulation development important in pharmaceutical manufacturing?
Formulation development determines how reliably a drug product can be manufactured at scale. A formulation that performs well in the laboratory may behave differently during commercial production because of changes in mixing, heat transfer, material properties, process conditions, or equipment.
What are the main challenges in formulation development?
Key formulation development challenges include physical and chemical instability, poor solubility, raw-material variability, scale-up, technology transfer, regulatory requirements, sustainability, and manufacturing consistency. Complex products such as nanoparticles and biologics can introduce additional process sensitivities.
How does Quality-by-Design support formulation development?
Quality-by-Design, or QbD, uses scientific knowledge and risk-based development to establish relationships between formulation variables, process parameters, and critical quality attributes. This can help development teams build quality into the product and process rather than relying primarily on end-product testing.
How are AI and digital technologies changing formulation development?
AI and digital technologies can support formulation screening, Design-of-Experiments, predictive modelling, stability assessment, process monitoring, and manufacturing control. AI-augmented development, model-informed control, digital experimentation, and data-driven manufacturing are all important areas for future development.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)